In children with idiopathic short stature (ISS), high-dose growth hormone (GH) therapy produces a significant increase in height, but its therapeutic benefit may be limited because it accelerates bone maturation and induces an earlier onset of puberty, according to a recent report.
Dr. J. M. Wit, from Leiden University Medical Center in the Netherlands, and colleagues assessed the 5-year outcomes of 35 children with ISS who were randomized to receive GH therapy or no treatment.
The subjects included 9 girls, 4 to 8 years of age, and 26 boys, 4 to 10 years of age. At enrollment, none of the children had signs of puberty and all had normal body proportions. The researchers’ findings are published in the September issue of the Archives of Disease in Childhood.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!